mpa Harvard Business School Desjardins Group The Boston Consulting Group Lloyd's Yale University DareDevil Strategies Amobee Publicis Groupe SA Pfizer Inc. Center for China in the World Economy (CCWE) Accel Partners The George Institute for Global Health Balderton Capital thesystemis Bloomberg New En

t National Hockey League New York University New York Yankees Noramco Inc. Norfolk Southern Corp. Pac-12 Enterprises LLC Paypal Holdings Inc. Pfizer Inc. Purdue Pharma LP Regeneron Pharmaceuticals Inc. Roku Inc. San Francisco 49ers San Jose Sharks SoFi Stadium Social Finance Inc. Sony Corp. So

roup LLC Marriott Vacations Worldwide Corp. Marvell Technology Group Ltd. Match Group Inc. McDonald's Corp. Microsoft Corp. Miramax Film Corp. Pfizer Inc. Power Solutions International Inc. PricewaterhouseCoopers LLP State Bar of California Steelcase Inc. EFTA00019089 --- PAGE BREAK --- HEALTH

ylan NV NASDAQ Inc. NatWest Markets PLC Novartis AG Oath Inc. Paramount Group Inc. Partnership for New York City Pennsylvania Bar Association Pfizer Inc. RELX PLC Regions Financial Corp. Royal Dutch Shell PLC Sierra Club SoulCycle Inc. Starboard Value LP State Bar of Michigan Temple University

Association New York University Nike Inc. Northeastern University Novartis AG PG&E Corp. Parker Drilling Company Pennsylvania Bar Association Pfizer Inc. Pogue Construction ITC To Probe Economic Effect Of Renewable Energy In Mass. EFTA00032343 --- PAGE BREAK --- The U.S. International Trade Commi

tional Basketball Association Nestle Oakland Raiders Ocwen Financial Corporation PHH Corporation Panasonic Corporation PepsiCo Inc. Petrobras Pfizer Inc. PhRMA Platinum Partners LP Prime Inc. Robert Half International Inc. SBM Offshore NV Scientific Games Corp. State Bar of California Stolt-Nie

izer-s-covid-vaccine-trial-plan-may-beat- rivals-to-early-look?smd=premium> (9/22, Langreth, 4.73M) reports, "The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals." The firms "plan a first look

-covid- vaccine-trial-in-days?smd=premium> (11/11, Langreth, 4.73M) reports that the "same US explosion of Covid-19 EFTA00137117 cases that helped Pfizer Inc. get results for its vaccine trial earlier this week is helping speed along Moderna's trial." Moderna "said Wednesday its study has accumulated more

e Trial Ready To Analyze Shot's Effectiveness. Bloomberg (11/11, Langreth, 4.73M) reports that the "same US explosion of Covid-19 cases that helped Pfizer Inc. get results for its vaccine trial earlier this week is helping speed along Moderna's trial." Moderna "said Wednesday its study has accumulated more

n people." Pfizer's COVID Vaccine Trial On Track To Beat Rivals. Bloomberg (9/22, Langreth, 4.73M) reports, "The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals." The firms "plan a first loo

starting Monday." Bloomberg adds that according to Mkhize, "the government will start a mass vaccination effort at 87 sites across the country using Pfizer Inc. doses administered to frontline health-care workers and the elderly." Pandemic Leading To Refugee Waves Across World. The New York Times (5/16, Jo

Impax Laboratories (IPXL), Kythera Biopharmaceuticals (KYTED, Mallinckrodt (MNK), Merck & Co., Inc. (MRK), Mylan Inc. (MYL), Perris° Company (PRGO), Pfizer Inc. (PFE), Sagent Pharmaceuticals (SGNT), Teva Pharmaceuticals (TEVA), Valeant Pharmaceuticals (VRX), Zoetis (ZTS) M. Morgan Equity Research Ratings Di

41-6. Public Companies Mentioned in this Report: Astellas Pharma (ALPMY — NR - $15.00) Eli Lilly (LLY — NR - $78.60) Merck & Co (MRK -NR-$54.54) Pfizer Inc. (PFE -NR-$36.13) Johnson & Johnson. (JNJ -NR-$130.41) 24 EFTA00810599 BROOKLINE CAPITAL MARKETS A Division of CIM Securities Veru, Inc. (VEIV

Take advantage of the sell-off in Healthcare by buying 3 large cap pharma names. Name Ticker Rating JPM Target Merck & Co., Inc. MRK OW $66 Pfizer Inc. PFE OW $40 Bristol-Myers Squibb Co. BMY OW $78 Source: Bloomberg 10/07/2015 2. Nikkei 400 linked structured note: We think there is furthe

Impax Laboratories (IPXL), Kythera Biopharmaceuticals (KYTH), Mallinckrodt (MNK), Merck & Co., Inc. (MRK), Mylan Inc. (MYL), Perrigo Company (PRGO), Pfizer Inc. (PFE), Sagent Pharmaceuticals (SGNT), Teva Pharmaceuticals (TEVA), Valeant Pharmaceuticals (VRX), Zoetis (ZTS) M. Morgan Equity Research Ratings Di

n people." Pfizer's COVID Vaccine Trial On Track To Beat Rivals. Bloomberg (9/22, Langreth, 4.73M) reports, "The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals." The firms "plan a first loo

e Trial Ready To Analyze Shot's Effectiveness. Bloomberg (11/11, Langreth, 4.73M) reports that the "same US explosion of Covid-19 cases that helped Pfizer Inc. get results for its vaccine trial earlier this week is helping speed along Moderna's trial." Moderna "said Wednesday its study has accumulated more

d Chief Executive Officer Desjardins Group The Boston Consulting Group Lloyd's Yale University DareDevil Strategies Amobee Publicis Groupe SA Pfizer Inc. Accel Partners Center for China in the World Economy (CCWE) The George Institute for Global Health Balderton Capital thesystemis Bloomberg Ne

Harvard Business School Desjardins Group The Boston Consulting Group Lloyd's Yale University DareDevil Strategies Amobee Publicis Groupe SA Pfizer Inc. Center for China in the World Economy (CCWE) Accel Partners The George Institute for Global Health Balderton Capital thesystemis Bloomberg Ne

Harvard Business School Desjardins Group The Boston Consulting Group Lloyd's Yale University DareDevil Strategies Amobee Publicis Groupe SA Pfizer Inc. Center for China in the World Economy (CCWE) Accel Partners The George Institute for Global Health Balderton Capital thesystemis Bloomberg Ne